Drug Trial Radar · NCT04580134
CLOZAPINE Response in Biotype-1
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
524
Planned (sponsor's estimate)
Start
Mar 1, 2022
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH); Beth Israel Deaconess Medical Center; Hartford Hospital; University of Georgia; University of Chicago
- First posted
- Oct 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.
Conditions
- Schizophrenia
- Schizoaffective Disorder
- Bipolar 1 Disorder
Interventions
clozapineDrug
Biotype 1 and Biotype 2
risperidoneDrug
Biotype 1 and Biotype 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the PANSS total scoreTime frame: Week 4, Week 10 and Week 18
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Hartford Healthcare
Hartford, Connecticut · Recruiting
University of Georgia
Athens, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.